Simon Rauber

Dr. Simon Rauber

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 July 2017 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
SRSimon Rauber
Simon Rauber
MLMarkus Luber
Markus Luber
SWStefanie Weber
Stefanie Weber
LMLisa Maul
Lisa Maul
ASAlina Soare
Alina Soare
ARAndreas Ramming
Andreas Ramming

30 January 2019 in Nature
Verified
Journal Article
Closed access
PDF file
TWThomas Wohlfahrt
Thomas Wohlfahrt
SRSimon Rauber
Simon Rauber
SUSteffen Uebe
Steffen Uebe
MLMarkus Luber
Markus Luber
ASAlina Soare
Alina Soare
ARAndreas Ramming
Andreas Ramming

20 July 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
AZAriella Zehender
Ariella Zehender
YLYi-Nan Li
Yi-Nan Li
NLNeng-Yu Lin
Neng-Yu Lin
ASAdrian Stefanica
Adrian Stefanica
JNJulian Nüchel
Julian Nüchel
JDJörg H. W. Distler
Jörg H. W. Distler
Activation of fibroblasts is essential for physiological tissue repair. Uncontrolled activation of fibroblasts, however, may lead to tissue fibrosis with organ dysfunction. Although several pathways capable of promoting fibroblast activation and tissue repair have been identified, their interplay in the context of chronic fibrotic diseases remains incompletely understood. Here, we provide evidence that transforming growth factor-β (TGFβ) activates autophagy by an epigenetic mechanism to amplify its profibrotic effects. TGFβ induces autophagy in fibrotic diseases by SMAD3-dependent downregulation of the H4K16 histone acetyltransferase MYST1, which regulates the expression of core components of the autophagy machinery such as ATG7 and BECLIN1. Activation of autophagy in fibroblasts promotes collagen release and is both, sufficient and required, to induce tissue fibrosis. Forced expression of MYST1 abrogates the stimulatory effects of TGFβ on autophagy and re-establishes the epigenetic control of autophagy in fibrotic conditions. Interference with the aberrant activation of autophagy inhibits TGFβ-induced fibroblast activation and ameliorates experimental dermal and pulmonary fibrosis. These findings link uncontrolled TGFβ signaling to aberrant autophagy and deregulated epigenetics in fibrotic diseases and may contribute to the development of therapeutic interventions in fibrotic diseases.

26 July 2019 in Arthritis & Rheumatology
Verified
Journal Article
Closed access
PDF file
ASAlina Soare
Alina Soare
HGHermina A. Györfi
Hermina A. Györfi
AMAlexandru E. Matei
Alexandru E. Matei
CDClara Dees
Clara Dees
SRSimon Rauber
Simon Rauber
JDJörg H. W. Distler
Jörg H. W. Distler

4 July 2024 in Annals of the Rheumatic Diseases
Verified
Journal Article
Open access
PDF file
KKKaterina Kachler
Katerina Kachler
DADarja Andreev
Darja Andreev
STShreeya Thapa
Shreeya Thapa
DRDmytro Royzman
Dmytro Royzman
Andreas GießlAndreas Gießl
Andreas Gießl
ABAline Bozec
Aline Bozec
Objectives Metabolic changes are crucially involved in osteoclast development and may contribute to bone degradation in rheumatoid arthritis (RA). The enzyme aconitate decarboxylase 1 (Acod1) is known to link the cellular function of monocyte-derived macrophages to their metabolic status. As osteoclasts derive from the monocyte lineage, we hypothesised a role for Acod1 and its metabolite itaconate in osteoclast differentiation and arthritis-associated bone loss. Methods Itaconate levels were measured in human peripheral blood mononuclear cells (PBMCs) of patients with RA and healthy controls by mass spectrometry. Human and murine osteoclasts were treated with the itaconate derivative 4-octyl-itaconate (4-OI) in vitro. We examined the impact of Acod1-deficiency and 4-OI treatment on bone erosion in mice using K/BxN serum-induced arthritis and human TNF transgenic (hTNFtg) mice. SCENITH and extracellular flux analyses were used to evaluate the metabolic activity of osteoclasts and osteoclast progenitors. Acod1-dependent and itaconate-dependent changes in the osteoclast transcriptome were identified by RNA sequencing. CRISPR/Cas9 gene editing was used to investigate the role of hypoxia-inducible factor (Hif)-1α in Acod1-mediated regulation of osteoclast development. Results Itaconate levels in PBMCs from patients with RA were inversely correlated with disease activity. Acod1-deficient mice exhibited increased osteoclast numbers and bone erosion in experimental arthritis while 4-OI treatment alleviated inflammatory bone loss in vivo and inhibited human and murine osteoclast differentiation in vitro. Mechanistically, Acod1 suppressed osteoclast differentiation by inhibiting succinate dehydrogenase-dependent production of reactive oxygen species and Hif1α-mediated induction of aerobic glycolysis. Conclusion Acod1 and itaconate are crucial regulators of osteoclast differentiation and bone loss in inflammatory arthritis.

15 February 2018 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
ASAlina Soare
Alina Soare
SWStefanie Weber
Stefanie Weber
LMLisa Maul
Lisa Maul
SRSimon Rauber
Simon Rauber
AGAna Maria Gheorghiu
Ana Maria Gheorghiu
ARAndreas Ramming
Andreas Ramming
Innate lymphoid cells (ILC) have a high potency for cytokine production independent of specific Ag stimulation. Imbalance of ILC subsets may influence cytokine production in humans and hence be associated with the development of inflammatory disease. Evidence for an imbalance of ILC homeostasis in human disease, however, is very limited to date. In this study we show that psoriatic arthritis (PsA), a severe disease of the joints depending on the activation of the IL-23/IL-17 pathway, is characterized by a skewed ILC homeostasis. Circulating ILC3s as potent source of IL-17/IL-22 were elevated in active PsA, whereas ILC2s, which produce proresolving cytokines, were decreased. The ILC2/ILC3 ratio was significantly correlated with clinical disease activity scores and the presence of imaging signs of joint inflammation and bone damage. Multivariable analysis showed that a high ILC2/ILC3 ratio is associated with remission in PsA, suggesting that specific alterations of ILC homeostasis control disease activity in PsA.